Research & Literature

Dystrophic epidermolysis bullosa: a review.

Shinkuma S

Clinical, cosmetic and investigational dermatology 2015; (8()):275-84 doi:10.2147/CCID.S54681.

Epidermolysis bullosa acquisita in a 17-year-old boy with Crohn's disease.

Russo I, Ferrazzi A, Zanetti I, Alaibac M

BMJ case reports 2015; (2015()).

Liver Transplant in a Patient With Acquired Epidermolysis Bullosa and Associated End-Stage Liver Disease.

Vennarecci G, Miglioresi L, Guglielmo N, et al.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2017; (15(3)):366-368 doi:10.6002/ect.2015.0018.

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

Kasperkiewicz M, Sadik CD, Bieber K, et al.

The Journal of investigative dermatology 2016; (136(1)):24-33 doi:10.1038/JID.2015.356.

Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA).

Seta V, Aucouturier F, Bonnefoy J, et al.

Journal of the American Academy of Dermatology 2016; (74(6)):1166-72.

A Case of Bullous Skin Disease Presenting with Odynophagia: A Diagnostic Challenge.

Kravvas G, Veitch D, Perrett CM

Case reports in dermatological medicine 2016; (2016()):2839104 doi:10.1155/2016/2839104.

Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.

Meijer JM, Diercks GF, Schmidt E, et al.

JAMA dermatology 2016; (152(8)):897-904 doi:10.1001/jamadermatol.2016.1099.

Clinical and immunological studies for 105 Japanese seropositive patients of epidermolysis bullosa acquisita examined at Kurume University.

Hashimoto T, Jin Z, Ishii N

Expert review of clinical immunology 2016; (12(8)):895-902 doi:10.1080/1744666X.2016.1196136.

Clinical features and diagnosis of epidermolysis bullosa acquisita.

Vorobyev A, Ludwig RJ, Schmidt E

Expert review of clinical immunology 2017; (13(2)):157-169 doi:10.1080/1744666X.2016.1221343.

Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis.

Schmidt T, Hoch M, Lotfi Jad SS, et al.

The British journal of dermatology 2017; (177(6)):1683-1692 doi:10.1111/bjd.15800.

Distinguishing Epidermolysis Bullosa Acquisita From Bullous Pemphigoid Without Direct Immunofluorescence.

Gardner KM, Crawford RI

Journal of cutaneous medicine and surgery 2018; (22(1)):22-24 doi:10.1177/1203475417722734.

Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin.

Goyal N, Rao R, Shenoi SD, et al.

Indian journal of dermatology, venereology and leprology 2017; (83(5)):550-555 doi:10.4103/ijdvl.IJDVL_678_16.

Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Amber KT, Murrell DF, Schmidt E, et al.

Clinical reviews in allergy & immunology 2018; (54(1)):26-51 doi:10.1007/s12016-017-8633-4.

Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases.

Goletz S, Zillikens D, Schmidt E

Experimental dermatology 2017; (26(12)):1154-1162 doi:10.1111/exd.13446.

Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases.

Meijer JM, Atefi I, Diercks GFH, et al.

Journal of the American Academy of Dermatology 2018; (78(4)):754-759.e6 doi:10.1016/j.jaad.2017.11.029.

International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita.

Prost-Squarcioni C, Caux F, Schmidt E, et al.

The British journal of dermatology 2018; (179(1)):30-41 doi:10.1111/bjd.16138.

Discrepancies in the evaluation of incapacity for work in a patient with epidermolysis bullosa acquisita between public pension fund and occupational medicine expert raise the issue of competencies.

Lalić H

Arhiv za higijenu rada i toksikologiju 2018; (69(1)):77-80.

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Mihai S, Hirose M, Wang Y, et al.

Frontiers in immunology 2018; (9()):535 doi:10.3389/fimmu.2018.00535.

Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.

Iwata H, Vorobyev A, Koga H, et al.

Orphanet journal of rare diseases 2018; (13(1)):153 doi:10.1186/s13023-018-0896-1.

Detection of u-serrated patterns in direct immunofluorescence images of autoimmune bullous diseases by inhibition-augmented COSFIRE filters.

Shi C, Meijer JM, Guo J, et al.

International journal of medical informatics 2019; (122()):27-36 doi:10.1016/j.ijmedinf.2018.11.007.

Steroid-induced Diabetes Complicating Treatment of Epidermolysis Bullosa Acquisita: A Preventable Treatment Complication Stresses the Importance of Primary Care Follow-up.

Byrd V, Nemeth A

Cureus 2018; (10(11)):e3608 doi:10.7759/cureus.3608.

[Epidermolysis bullosa acquisita].

Hofmann SC, Weidinger A

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(4)):265-270 doi:10.1007/s00105-019-4387-7.

Ocular involvement in epidermolysis bullosa acquisita with long-term follow-up.

Rousseau A, Prost-Squarcioni C, Doan S, et al.

The British journal of ophthalmology 2020; (104(2)):235-240 doi:10.1136/bjophthalmol-2019-313960.

Ocular Manifestations and Management of Autoimmune Bullous Diseases.

Feizi S, Roshandel D

Journal of ophthalmic & vision research 2019; (14(2)):195-210 doi:10.4103/jovr.jovr_86_18.

Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.

Santi CG, Gripp AC, Roselino AM, et al.

Anais brasileiros de dermatologia 2019; (94(2 Suppl 1)):33-47 doi:10.1590/abd1806-4841.2019940207.

The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis Bullosa Acquisita.

Thieme M, Bieber K, Sezin T, et al.

The Journal of investigative dermatology 2019; (139(11)):2381-2384.e3 doi:10.1016/j.jid.2019.03.1159.

Epidermolysis bullosa acquisita: A comprehensive review.

Kridin K, Kneiber D, Kowalski EH, et al.

Autoimmunity reviews 2019; (18(8)):786-795 doi:10.1016/j.autrev.2019.06.007.

High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease.

Hoffmann JHO, Enk AH

Frontiers in immunology 2019; (10()):1090 doi:10.3389/fimmu.2019.01090.

Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature.

Beiu C, Mihai M, Popa L, et al.

Cureus 2019; (11(12)):e6386 doi:10.7759/cureus.6386.

Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury.

Hundt JE, Iwata H, Pieper M, et al.

Scientific reports 2020; (10(1)):4509 doi:10.1038/s41598-020-60233-w.

Epidermolysis Bullosa Acquisita: A Case Report.

Kumetz EA, Meyerle JH, Rivard SC

The American journal of case reports 2020; (21()):e919432 doi:10.12659/AJCR.919432.

Propranolol Off-Target: A New Therapeutic Option in Neutrophil-Dependent Dermatoses?

Maglie R, Solimani F, Quintarelli L, Hertl M

The Journal of investigative dermatology 2020; (140(12)):2326-2329 doi:10.1016/j.jid.2020.06.002.

Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases.

Holtsche MM, van Beek N, Künstner A, et al.

Acta dermato-venereologica 2021; (101(3)):adv00410 doi:10.2340/00015555-3748.

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Holtsche MM, van Beek N, Hashimoto T, et al.

Acta dermato-venereologica 2021; (101(3)):adv00420 doi:10.2340/00015555-3774.

Therapeutic approaches and targets for treatment of autoimmune bullous diseases.

Bardazzi F, Loi C, Chessa Marco A, et al.

Dermatologic therapy 2021; (34(5)):e15032 doi:10.1111/dth.15032.

Anti-P 200 pemphigoid - The most common floor binding subepidermal autoimmune bullous disease in a tertiary care center in south India.

Rai R, Anand JB, Shanmugasekar C, et al.

Indian journal of dermatology, venereology and leprology 2021; (87(6)):787-791.

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Rashid H, Lamberts A, Borradori L, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(9)):1750-1764 doi:10.1111/jdv.17397.

Pediatric epidermolysis bullosa acquisita: A review.

Hignett E, Sami N

Pediatric dermatology 2021; (38(5)):1047-1050 doi:10.1111/pde.14722.

Epidermolysis bullosa acquisita treated with ustekinumab: A case report.

Prosty C, Guirguis J, Chergui M, et al.

SAGE open medical case reports 2022; (10()):2050313X221091600 doi:10.1177/2050313X221091600.

Epidermolysis bullosa acquisita.

Miyamoto D, Gordilho JO, Santi CG, Porro AM

Anais brasileiros de dermatologia 2022; (97(4)):409-423 doi:10.1016/j.abd.2021.09.010.

Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.

Tešanović Perković D, Bukvić Mokos Z, Marinović B

Journal of clinical medicine 2023; (12(3)) doi:10.3390/jcm12031139.

A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.

Kianfar N, Dasdar S, Daneshpazhooh M, et al.

Experimental dermatology 2023; (32(7)):934-944 doi:10.1111/exd.14829.

Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review.

Szymański K, Kowalewski C, Pietrzyk E, Woźniak K

Frontiers in immunology 2023; (14()):1214011 doi:10.3389/fimmu.2023.1214011.

Involvement of palms and soles in patients with autoimmune bullous diseases: a comparative analysis of a diagnostically relevant localization.

Jałowska M, Spałek M, Bowszyc-Dmochowska M, et al.

Frontiers in immunology 2023; (14()):1227855 doi:10.3389/fimmu.2023.1227855.

Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita.

Gross N, Marketon J, Mousavi S, et al.

Frontiers in immunology 2024; (15()):1343299 doi:10.3389/fimmu.2024.1343299.

Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.

Kianfar N, Dasdar S, Marashi A, et al.

The Journal of clinical and aesthetic dermatology 2024; (17(7)):24-36.

Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita.

Bratsos SP, Demir Z, Mee JB, et al.

Clinical and experimental dermatology 2024; (50(1)):97-103 doi:10.1093/ced/llae283.

Clinical characteristics and outcomes of autoimmune blistering diseases in Japan.

Encarnacion MRN, Kawai R, Kuwabiraki H, et al.

The Journal of dermatology 2025; (52(2)):299-308 doi:10.1111/1346-8138.17518.

An Exceedingly Rare Case of Mechanobullous Epidermolysis Bullosa Acquisita in a Prepubertal Child: A Review of the Clinical and Laboratory Considerations.

Bratborska AW, Spałek M, Bowszyc-Dmochowska M, Dmochowski M

Antibodies (Basel, Switzerland) 2025; (14(2)) doi:10.3390/antib14020034.

A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.

Myers EL, Culton DA

Dermatology and therapy 2025; (15(7)):1755-1770 doi:10.1007/s13555-025-01444-9.

Complexities of care in a pediatric patient with epidermolysis bullosa acquisita and duchenne muscular dystrophy: a case report.

Al-Shami K, Haddad Z, Mohammad Yousef Abuelrub M, et al.

Journal of medical case reports 2025; (19(1)):330 doi:10.1186/s13256-025-05395-9.

Type VII Collagen Disorders Simplified.

Camisa C

Cutis 2025; (116(2)):205-209, 214, E3-E4 doi:10.12788/cutis.1267.

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Kawamoto H, Sasaki N, Ueda Y, et al.

Frontiers in immunology 2025; (16()):1724412 doi:10.3389/fimmu.2025.1724412.

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.

Ng KL, Karunaratne KI

Cureus 2026; (18(2)):e103568 doi:10.7759/cureus.103568.

HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease.

Basra R, Naderi R, Yogarajah S, et al.

Clinical and experimental dermatology 2026; (51(8)):1466-1469 doi:10.1093/ced/llag052.